Glimepirida Cinfa

Glimepirida Cinfa is a prescription‑only oral medication that contains the active ingredient glimepiride, a second‑generation sulfonylurea. It is marketed in the European Union and is supplied as tablets, with strengths that correspond to the authorized dosages for the product. The drug belongs to the antidiabetic, oral hypoglycemic therapeutic class and works by stimulating insulin release from pancreatic β‑cells, and is used under medical supervision to manage blood glucose levels.

Glimepirida Cinfa is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus when diet, exercise, and lifestyle measures alone are insufficient.

- As monotherapy in patients whose glycemic control is not achieved with non‑pharmacologic measures. - In combination with metformin when additional glucose lowering is required. - As part of a fixed‑dose combination regimen with other oral antidiabetics, if approved. - For patients who can tolerate sulfonylureas and have preserved pancreatic β‑cell function. - To achieve target HbA1c levels as part of an individualized treatment plan.

The safety profile of Glimepirida Cinfa includes a range of adverse effects that are classified by frequency and clinical significance.

Common: - Mild hypoglycemia, especially if meals are skipped or delayed. - Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia. - Headache or dizziness. - Weight gain due to increased insulin activity.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness). - Allergic reactions including rash, pruritus, or angio‑edema. - Hematologic abnormalities such as leukopenia or thrombocytopenia.

Before prescribing Glimepirida Cinfa, clinicians should evaluate several patient‑specific factors and monitor for potential risks during therapy.

- Assess renal and hepatic function; dose adjustment may be needed in impairment. - Verify that the patient has adequate pancreatic β‑cell reserve. - Caution in elderly patients due to increased susceptibility to hypoglycemia. - Avoid use during pregnancy and lactation unless benefits outweigh risks. - Review concomitant use of other hypoglycemic agents to prevent additive effects. - Monitor for signs of cardiovascular disease, as sulfonylureas may affect cardiac ischemic preconditioning. - Educate patients on recognizing and managing hypoglycemia.

Glimepirida Cinfa can interact with several medications, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid: - Concurrent use with other sulfonylureas or insulin, which may cause profound hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that increase glimepiride plasma concentrations. - MAO‑B inhibitors (e.g., selegiline) that may potentiate hypoglycemic effects.

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms. - Thiazide diuretics, which may raise blood glucose levels. - Corticosteroids or atypical antipsychotics that can reduce glimepiride efficacy. - NSAIDs, especially high‑dose ibuprofen, that may affect renal function and drug clearance.